Lexicon Pharmaceuticals Inc (LXRX) - Total Assets
Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) holds total assets worth $268.82 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lexicon Pharmaceuticals Inc - Total Assets Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Lexicon Pharmaceuticals Inc (LXRX) market capitalisation for the company's overall valuation and market capitalisation.
Lexicon Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Lexicon Pharmaceuticals Inc's total assets of $268.82 Million consist of 55.1% current assets and 44.9% non-current assets. Review Lexicon Pharmaceuticals Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.6% |
| Accounts Receivable | $2.38 Million | 1.3% |
| Inventory | $281.00K | 0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $44.54 Million | 24.1% |
Asset Composition Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LXRX share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lexicon Pharmaceuticals Inc's current assets represent 55.1% of total assets in 2025, a decrease from 56.5% in 1999.
- Cash Position: Cash and equivalents constituted 18.6% of total assets in 2025, up from 9.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 24.1% of total assets.
Lexicon Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Lexicon Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Lexicon Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.79 | 2.22 | 3.76 |
| Quick Ratio | 18.77 | 2.22 | 3.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $176.13 Million | $135.11 Million | $90.44 Million |
Lexicon Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Lexicon Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.16 |
| Latest Market Cap to Assets Ratio | 4.54 |
| Asset Growth Rate (YoY) | -38.0% |
| Total Assets | $184.99 Million |
| Market Capitalization | $839.53 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lexicon Pharmaceuticals Inc's assets at a significant premium (4.54x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Lexicon Pharmaceuticals Inc's assets decreased by 38.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual total assets of Lexicon Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $184.99 Million | -38.01% |
| 2024-12-31 | $298.42 Million | +30.07% |
| 2023-12-31 | $229.43 Million | +18.08% |
| 2022-12-31 | $194.30 Million | +41.92% |
| 2021-12-31 | $136.91 Million | -32.82% |
| 2020-12-31 | $203.79 Million | -51.21% |
| 2019-12-31 | $417.71 Million | +47.01% |
| 2018-12-31 | $284.14 Million | -34.91% |
| 2017-12-31 | $436.54 Million | -8.22% |
| 2016-12-31 | $475.62 Million | -27.37% |
| 2015-12-31 | $654.83 Million | +38.92% |
| 2014-12-31 | $471.38 Million | +71.93% |
| 2013-12-31 | $274.16 Million | -26.26% |
| 2012-12-31 | $371.78 Million | -13.64% |
| 2011-12-31 | $430.51 Million | +17.34% |
| 2010-12-31 | $366.88 Million | +42.33% |
| 2009-12-31 | $257.76 Million | -1.43% |
| 2008-12-31 | $261.51 Million | -29.19% |
| 2007-12-31 | $369.30 Million | +94.09% |
| 2006-12-31 | $190.27 Million | -13.01% |
| 2005-12-31 | $218.71 Million | +3.18% |
| 2004-12-31 | $211.98 Million | -25.41% |
| 2003-12-31 | $284.20 Million | +40.85% |
| 2002-12-31 | $201.77 Million | -15.92% |
| 2001-12-31 | $239.99 Million | +8.74% |
| 2000-12-31 | $220.69 Million | +889.65% |
| 1999-12-31 | $22.30 Million | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more